Medicilon Assists ABM Therapeutics to Obtain US FDA Orphan Drug Qualification for ABM-1310 for the T

Shanghai, China/San Diego,USA - August 2, 2023, ABM Therapeutics announced that its self-developed small molecule BRAF inhibitor ABM-1310 has obtained orphan drug qualification from the US FDA for the treatment of BRAF V600 mutant brain glioblastoma (GBM).

In the research and development of ABM-1310, the chemical FTE (Full-time equivalent) team of Shanghai Medicilon Inc provided drug discovery services in a flexible cooperation mode.  It has laid a solid foundation for ABM Therapeutics' ABM-1310 to obtain the US FDA Orphan Drug Qualification.

Medicilon Chemical FTE Team
Facilitate Rapid Discovery of Innovative Drugs

The chemical FTE team of Medicilon can serve clients in different stages of drug development, including the generation and optimization of hit compounds, the identification and optimization of lead compounds, synthesis amplification chemical process research and other services.  This collaboration model is based on client and project needs, and can flexibly adjust R&D personnel allocation, experimental plans and project priorities.  In addition, the FTE team can not only synthesize according to the synthetic circuit designed by the client, but also reasonably design the synthetic circuit according to the client's idea.  Currently, the Medicilon FTE team has successfully empowered many pharmaceutical companies and scientific research institutions around the world to develop drugs in a compliant, safe and efficient manner.

About ABM Therapeutics

ABM Therapeutics is a clinical stage new drug research and development company.  The company focuses on the R&D of small molecule drugs that can break through the blood-brain barrier.  Its small-molecule targeted inhibitors under development can break through the blood-brain barrier, significantly improve the efficiency of drugs entering the brain, and are expected to solve the problem of brain metastasis of tumors.  ABM Therapeutics has developed steadily since its establishment, and has established R&D operation centers in the United States and China.  Through independent research and development, the company has built a rich R&D pipeline for brain-injecting drugs, and has become a brain-penetrating kinase drug R&D platform (BPKddTM) for anti-cancer drugs and small-molecule drugs for brain-injecting drugs.

About Medicilon

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of 2022, Medicilon has provided new drug R&D services to more than 1,840 clients around the world, and participated in the R&D of 330 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.